Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes

Stanley A. Schwartz

doi:10.1007/BF02914366

Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes

Stanley A. Schwartz

Medicine

University at Buffalo

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients

Original language	English
Pages (from-to)	1-12
Number of pages	12
Journal	Clinical Reviews in Allergy
Volume	10
Issue number	1-2
DOIs	https://doi.org/10.1007/BF02914366
State	Published - Mar 1992

Access to Document

10.1007/BF02914366

Cite this

@article{ab8b69deb8624ce7969492c1ee79d58f,

title = "Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes",

abstract = "IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients",

author = "Schwartz, \{Stanley A.\}",

year = "1992",

month = mar,

doi = "10.1007/BF02914366",

language = "English",

volume = "10",

pages = "1--12",

journal = "Clinical Reviews in Allergy",

issn = "0731-8235",

publisher = "Springer",

number = "1-2",

}

TY - JOUR

T1 - Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes

AU - Schwartz, Stanley A.

PY - 1992/3

Y1 - 1992/3

N2 - IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients

AB - IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients

UR - https://www.scopus.com/pages/publications/0026828917

U2 - 10.1007/BF02914366

DO - 10.1007/BF02914366

M3 - Article

C2 - 1606517

SN - 0731-8235

VL - 10

SP - 1

EP - 12

JO - Clinical Reviews in Allergy

JF - Clinical Reviews in Allergy

IS - 1-2

ER -

Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this